Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

[1]  S. Durum,et al.  Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations , 2018, Oncotarget.

[2]  A. Letai,et al.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.

[3]  W. Bolosky,et al.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies , 2017, Proceedings of the National Academy of Sciences.

[4]  Krister Wennerberg,et al.  Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513] , 2017, Computational and structural biotechnology journal.

[5]  T. Aittokallio,et al.  JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. , 2015, Blood.

[6]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[7]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[8]  Krister Wennerberg,et al.  Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513] , 2017, Computational and structural biotechnology journal.

[9]  Paul Shinn,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[10]  Damien Y. Duveau,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[11]  C. Reyes,et al.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States , 2015, Annals of Hematology.

[12]  Daniel J Weisdorf,et al.  Acute Myeloid Leukemia. , 2015, The New England journal of medicine.

[13]  R. Dickins,et al.  Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors , 2013, Cell reports.

[14]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[15]  A. Roulston,et al.  Programming cancer cells for high expression levels of Mcl1 , 2013, EMBO reports.

[16]  N. Shimada,et al.  A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers , 2013, International Journal of Hematology.

[17]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[18]  R. Jove,et al.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  H. Kantarjian,et al.  Acute myeloid leukemia , 2018, Methods in Molecular Biology.